EXPERT study: Randomized phase III trial of radical surgery and postoperative mFOLFOX6 versus perioperative mFOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases (CLMs).

被引：1
|
作者：
Mise, Yoshihiro
Hasegawa, Kiyoshi
Oba, Masaru
Yamaguchi, Kensei
Uetake, Hiroyuki
Yoshino, Takayuki
Morita, Satoshi
Takahashi, Keiichi
Unno, Michiaki
Shimada, Yasuhiro
Muro, Kei
Yoshida, Kazuhiro
Mori, Masaki
Baba, Hideo
Shimada, Mitsuo
Saiura, Akio
Matsumura, Masaru
Ishigure, Kiyoshi
Sugihara, Kenichi
Kokudo, Norihiro
机构：
[1] Japanese Fdn Canc Res, Tokyo, Japan
[2] Univ Tokyo, Tokyo, Japan
[3] Univ Tokyo, Grad Sch Med, Dept Surg, Hepatobiliary Pancreat Surg Div, Tokyo, Japan
[4] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[5] Tokyo Med & Dent Univ, Dept Specialized Surg, Tokyo, Japan
[6] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[7] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan
[8] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Surg, Tokyo, Japan
[9] Tohoku Univ, Grad Sch Med, Sendai, Miyagi, Japan
[10] Kochi Hlth Sci Ctr, Kochi, Japan
[11] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan
[12] Gifu Univ, Grad Sch Med, Dept Surg Oncol, Gifu, Japan
[13] Osaka Univ, Grad Sch Med, Dept Gastroenterol Surg, Suita, Osaka, Japan
[14] Kumamoto Univ, Grad Sch Med Sci, Dept Gastroenterol Surg, Kumamoto, Japan
[15] Tokushima Univ, Tokushima, Japan
[16] Konan Kosei Hosp, Konan, Japan
[17] Tokyo Med & Dent Univ, Tokyo, Japan
[18] Natl Ctr Global Hlth & Med, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.652
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
652
引用
收藏
页数：2
相关论文
共 50 条
  • [41] NSABP FC-6: Surgical conversion rate in colorectal cancer patients with unresectable, KRAS wild-type liver metastases receiving mFOLFOX7 plus cetuximab
    Wagman, Lawrence D.
    Geller, David A.
    Jacobs, Samuel A.
    Petrelli, Nicholas J.
    Allegra, Carmen J.
    Lipchik, Corey
    Pogue-Geile, Katherine L.
    Srinivasan, Ashok
    Wang, Ying
    O'Connell, Michael J.
    JOURNAL OF SURGICAL ONCOLOGY, 2022, 126 (08) : 1494 - 1503
  • [42] Randomized, phase II study of bevacizumab with mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: Resectability and safety in OLIVIA
    Gruenberger, Thomas
    Bridgewater, John A.
    Chau, Ian
    Garcia Alfonso, Pilar
    Rivoire, Michel
    Lasserre, Susan
    Waterkamp, Daniel
    Adam, Rene
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] PARADIGM study: A multicenter, randomized, phase III study of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer.
    Yoshino, Takayuki
    Uetake, Hiroyuki
    Tsuchihara, Katsuya
    Shitara, Kohei
    Yamazaki, Kentaro
    Oki, Eiji
    Sato, Takeo
    Naitoh, Takeshi
    Komatsu, Yoshito
    Kato, Takeshi
    Iwasaki, Kouji
    Soeda, Junpei
    Hihara, Masamitsu
    Yamanaka, Takeharu
    Ochiai, Atsushi
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [44] Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of unresectable RAS/BRAF wild-type metastatic colorectal cancer (mCRC) patients: Results of the phase III randomized TRIPLETE study by GONO
    Rossini, D.
    Antoniotti, C.
    Lonardi, S.
    Pietrantonio, F.
    Marmorino, F.
    Antonuzzo, L.
    Boccaccino, A.
    Randon, G.
    Giommoni, E.
    Pozzo, C.
    Moretto, R.
    De Grandis, M.
    Viola, M.
    Passardi, A.
    Borelli, B.
    Buonadonna, A.
    Masi, G.
    Formica, V.
    Aprile, G.
    Boni, L.
    Cremolini, C.
    ANNALS OF ONCOLOGY, 2022, 33 : S381 - S381
  • [45] PATHOLOGICAL RESPONSE OF SYNCHRONOUS LIVER METASTASES FROM COLORECTAL CANCER TREATED WITH BEVACIZUMAB PLUS MFOLFOX6 IN AN ANALYSIS OF A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY
    Katayose, Y.
    Yamauchi, J.
    Oikawa, M.
    Sakurai, N.
    Musya, H.
    Shimamura, H.
    Miura, K.
    Nakagawa, K.
    Egawa, S.
    Unno, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 211 - 211
  • [46] Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer (mCRC): Results of the phase III randomized TRIPLETE study by GONO
    Cremolini, Chiara
    Rossini, Daniele
    Lonardi, Sara
    Antoniotti, Carlotta
    Pietrantonio, Filippo
    Marmorino, Federica
    Antonuzzo, Lorenzo
    Boccaccino, Alessandra
    Randon, Giovanni
    Giommoni, Elisa
    Pozzo, Carmelo
    Moretto, Roberto
    De Grandis, Maria Caterina
    Viola, Massimo Giuseppe
    Passardi, Alessandro
    Buonadonna, Angela
    Formica, Vincenzo
    Aprile, Giuseppe
    Boni, Luca
    Masi, Gianluca
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [47] Updated efficacy/safety findings from a randomized, phase 2 study of bevacizumab plus mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer (OLIVIA study)
    Bridgewater, J.
    Adam, R.
    Chau, I.
    Garcia Alfonso, P.
    Rivoire, M.
    Lasserre, S.
    Loeffler, M.
    Gruenberger, T.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S483 - S484
  • [48] A PHASE II MULTICENTER TRIAL OF NEOADJUVANT CHEMOTHERAPY WITH BEVACIZUMAB PLUS MFOLFOX6 FOR RESECTABLE CASES OF SYNCHRONOUS LIVER METASTASIS FROM COLORECTAL CANCER: THE FIRST INTERIM ANALYSIS
    Katayose, Y.
    Miura, K.
    Yamauchi, J.
    Sakurai, N.
    Musya, H.
    Oikawa, M.
    Uchiyama, T.
    Narushima, Y.
    Nakagawa, K.
    Unno, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 214 - 214
  • [49] Perioperative chemotherapy with mFOLFOX6 or CAPOX for patients with locally advanced colon cancer (OPTICAL): A multicenter, randomized, phase 3 trial.
    Hu, Huabin
    Huang, Meijin
    Li, Yunfeng
    Wang, Ziqiang
    Wang, Xiaozhong
    Liu, Ping
    Zhang, Ruyi
    Zhang, Hao
    Huang, Zhongcheng
    Pei, Haiping
    Zeng, Yongming
    Lai, Jiajun
    Chen, Wenbin
    Chen, Jiansi
    Ding, Zhijie
    Wei, Hongbo
    Xu, Qingwen
    Chen, Jigui
    Wang, Jianping
    Deng, Yanhong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [50] Phase Ib Study of Drozitumab Combined with First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer
    Lima, Caio M. Rocha
    Bayraktar, Soley
    Flores, Aurea M.
    MacIntyre, Jessica
    Montero, Alberto
    Baranda, Joaquina C.
    Wallmark, John
    Portera, Chia
    Raja, Rajiv
    Stern, Howard
    Royer-Joo, Stephanie
    Amler, Lukas C.
    CANCER INVESTIGATION, 2012, 30 (10) : 727 - 731
12345